1.17

4.10% -0.05

After Hours: 1.17

Bright Minds Biosciences Inc (DRUG)

Overview News Price History Discussions Forecast Stock Split

Bright Minds Biosciences Inc stock is traded at $1.17, with a volume of 2,777. It is down -4.10% in the last 24 hours and up +10.38% over the past month. Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Previous Close:

$1.22

Open:

$1.24

24h Volume:

2,777

Relative Volume:

0.03

Market Cap:

$5.22M

Revenue:

Net Income/Loss:

$-4.98M

P/E Ratio:

-0.6028

EPS:

-1.9408

Net Cash Flow:

$-3.85M

1W Performance:

-1.85%

1M Performance:

+10.38%

6M Performance:

-2.49%

1Y Performance:

-26.88%

1-Day Range:

$1.17

$1.24

1-Week Range:

$1.17

$1.2488

52-Week Range:

$0.93

$2.39

Bright Minds Biosciences Inc Stock (DRUG) Company Profile

Name

Bright Minds Biosciences Inc

Sector

Healthcare (1190)

Industry

Biotechnology (681)

Phone

Address

Employee

Twitter

Next Earnings Date

Latest SEC Filings

DRUG's Discussions on Twitter

Bright Minds Biosciences Inc Stock (DRUG) Latest News

Sep 26, 2024

Nickel Rock Resources Inc. (BFF.V) (CVE:BFF) Stock Price Passes Below Fifty Day Moving Average of $0.14 - Defense World

Sep 26, 2024

Sep 25, 2024

Bright Minds Biosciences Initiates the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy - Barchart

Sep 25, 2024

Lykos laying off 75% of workforce following FDA rejection of psychedelic drug for PTSD - MSN

Sep 25, 2024

Sep 24, 2024

Epilepsy Pipeline Insights, Clinical Trials, Treatment Drugs, And Companies 2024 - Barchart

Sep 24, 2024

Sep 19, 2024

Premier Asset Management Group (LON:PAM) Stock Price Crosses Above 50 Day Moving Average of $183.50 - Defense World

Sep 19, 2024

Bright Minds Biosciences to Host Investor & Analyst KOL Event on September 25th - Yahoo Finance

Sep 19, 2024

Invesco Income Growth Trust (LON:IVI) Shares Pass Above Fifty Day Moving Average of $278.00 - Defense World

Sep 19, 2024

Excalibur (Cayman) Ltd Svf Sells 7,500,000 Shares of Compass, Inc. (NYSE:COMP) Stock - Defense World

Sep 19, 2024

Genetic Disorder L.P. Kkr Sells 5,800,000 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) Stock - Defense World

Sep 19, 2024

FRP Holdings, Inc. (NASDAQ:FRPH) Shares Bought by Bank of New York Mellon Corp - Defense World

Sep 19, 2024

Surge Energy Inc. (TSE:SGY) Receives Consensus Recommendation of “Buy” from Analysts - Defense World

Sep 19, 2024

Rhumbline Advisers Purchases 892 Shares of TotalEnergies SE (NYSE:TTE) - Defense World

Sep 19, 2024

Acadian Asset Management LLC Has $516,000 Holdings in Zebra Technologies Co. (NASDAQ:ZBRA) - Defense World

Sep 19, 2024

Commonwealth Equity Services LLC Has $811,000 Stock Holdings in Innovator Growth Accelerated Plus ETF – October (BATS:QTOC) - Defense World

Sep 19, 2024

Sep 13, 2024

Bright Minds Biosciences launches Phase II trial of absence epilepsy treatment - Yahoo Finance

Sep 13, 2024

Aug 27, 2024